<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02069509</url>
  </required_header>
  <id_info>
    <org_study_id>HEALTH-F2-2010- 242193</org_study_id>
    <nct_id>NCT02069509</nct_id>
  </id_info>
  <brief_title>Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)</brief_title>
  <acronym>EFACTS</acronym>
  <official_title>Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Friedreich's Ataxia Consortium for Translational Studies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Friedreich's Ataxia Consortium for Translational Studies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre, multi-national, prospective, observational study of Friedreich's
      Ataxia (FRDA) with a control group to:

        -  obtain natural history data on individuals affected by FRDA

        -  relate clinical assessments and results from proteomic analyses

        -  expedite identification and recruitment of participants for clinical trials

        -  develop and validate sensitive and reliable outcome measures for detecting onset and
           change over the natural course of FRDA which may also be potential outcome measures for
           use in future clinical trials and clinical care

        -  plan for future research studies
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The EFACTS patient registry integrates prospectively and systematically collected clinical
      research data (e.g. clinical tests, demographical characteristics) with access to biological
      specimens (e.g. blood, urine) obtained from individuals with genetically confirmed FRDA and
      unrelated control research participants.

      The EFACTS patient registry started out as a 4-year study and is currently running without a
      set end date. Eligible subjects are assessed at annual study visits on the clinical symptoms
      and signs of the disease. At each study visit, general clinical, motor function, cognitive,
      and Quality of Life assessments are administered. In addition, participants are providing bio
      samples for the purposes of genetic testing and for research to identify valuable biomarkers
      of FRDA. Biological specimens and clinical data are made available to qualified scientists
      within the EFACTS network whose projects are reviewed and approved by the EFACTS Steering
      Committee. Research projects should aim to advance scientific knowledge towards establishing
      clinically effective treatments that delay onset and/or slow the progression of the disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Years</target_duration>
  <primary_outcome>
    <measure>Disease progression as assessed by clinical examination</measure>
    <time_frame>Participants are followed with annual assessments</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Friedreich's Ataxia</condition>
  <arm_group>
    <arm_group_label>Control research participants</arm_group_label>
    <description>diagnosis of FRDA genetically excluded</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FRDA patients</arm_group_label>
    <description>with genetically confirmed diagnosis of FRDA</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, urine, centrifugate of serum, EDTA, citrate blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with a genetically confirmed diagnosis of FRDA and control research
        participants with genetically excluded diagnosis of FRDA.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Genetic diagnosis of FRDA

          -  For control research participants: genetically confirmed absence of FRDA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jörg B. Schulz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Aachen, Dept. of Neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paola Giunti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College of London, Institute of Neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Caterina Mariotti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Istituto Neurologico Carlo Besta, Unit of Genetics of Neurodegenerative and Metabolic Diseases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco J. Rodriguez de Rivera Garrido, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>La Paz University Hospital, Universidad Autónoma de Madrid, Dept. of Neurology,</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandra Dürr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Pitié Salpêtrière, ICM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Klopstock, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Munich, Dept. of Neurology with Friedrich-Baur-Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sylvia Boesch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Innsbruck, Department of Neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massimo Pandolfo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université Libre de Bruxelles, Service de Neurologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ludger Schöls, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tübingen, Dept. of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Klockgether, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Bonn, Dept. of Neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katrin Bürk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Philipps University of Marburg, Dept. of Neurology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jörg B. Schulz, MD</last_name>
    <phone>0049-241-80-89600</phone>
    <email>jschulz@ukaachen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathrin Reetz, MD</last_name>
    <phone>0049-241-80-89600</phone>
    <email>kreetz@ukaachen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University Innsbruck, Department of Neurology</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Boesch, MD</last_name>
      <email>sylvia.boesch@i-med.ac.at</email>
    </contact>
    <investigator>
      <last_name>Sylvia Boesch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wolfgang Nachbauer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Université Libre de Bruxelles</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myriam Rai, PhD</last_name>
      <email>myriam.rai@ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Massimo Pandolfo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chantal Depondt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Dürr, MD</last_name>
      <email>alexandra.durr@upmc.fr</email>
    </contact>
    <investigator>
      <last_name>Alexandra Dürr, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Perrine Charles, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôptal de Hautepierre, Department of Neurology</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu Anheim, MD</last_name>
      <email>mathieu.anheim@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Mathieu Anheim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Aachen, Dept. of Neurology</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Schulz, MD</last_name>
      <email>jschulz@ukaachen.de</email>
    </contact>
    <investigator>
      <last_name>Jörg B. Schulz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel Dafotakis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn, Dept. of Neurology</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Schneider, MD</last_name>
      <email>christine.schneider@dzne.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Klockgether, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Schneider, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Philipps University Marburg, Dept. of Neurology</name>
      <address>
        <city>Marburg</city>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Bürk, MD</last_name>
      <email>buerk@med.uni-marburg.de</email>
    </contact>
    <investigator>
      <last_name>Katrin Bürk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Munich, Dept. of Neurology</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Karin, MD</last_name>
      <email>ivan.karin@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Klopstock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ivan Karin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tübingen, Dept. of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludger Schöls, MD</last_name>
      <email>ludger.schoels@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Jennifer Müller vom Hagen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ludger Schöls, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Neurologico Carlo Besta</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caterina Mariotti, MD</last_name>
      <email>mariotti.c@istituto-besta.it</email>
    </contact>
    <investigator>
      <last_name>Caterina Mariotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorenzo Nanetti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marta Panzeri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz, Servicio de Neurologia</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco J. Rodriguez de Rivera Garrido, MD</last_name>
      <email>rodriguezderivera@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Francisco J. Rodriguez de Rivera Garrido, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College of London, Institute of Neurology</name>
      <address>
        <city>London</city>
        <zip>WC1N 3 BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Giunti, MD</last_name>
      <email>pgiunti@ion.ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Paola Giunti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael H. Parkinson, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.e-facts.eu</url>
    <description>EFACTS Registry</description>
  </link>
  <reference>
    <citation>Reetz K, Dogan I, Costa AS, Dafotakis M, Fedosov K, Giunti P, Parkinson MH, Sweeney MG, Mariotti C, Panzeri M, Nanetti L, Arpa J, Sanz-Gallego I, Durr A, Charles P, Boesch S, Nachbauer W, Klopstock T, Karin I, Depondt C, vom Hagen JM, Schöls L, Giordano IA, Klockgether T, Bürk K, Pandolfo M, Schulz JB. Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurol. 2015 Feb;14(2):174-82. doi: 10.1016/S1474-4422(14)70321-7. Epub 2015 Jan 5.</citation>
    <PMID>25566998</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2014</study_first_submitted>
  <study_first_submitted_qc>February 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2014</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Friedreich's Ataxia</keyword>
  <keyword>EFACTS</keyword>
  <keyword>FRDA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

